Trials / Completed
CompletedNCT06286475
A Study of VRG50635 in Healthy Volunteers
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of VRG50635 in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Verge Genomics · Industry
- Sex
- All
- Age
- 19 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The primary objectives of this study are to investigate the safety and tolerability of VRG50635 and to determine how VRG50635 is absorbed by the body.
Detailed description
This is a Phase 1, randomized, single-center study conducted in 2 parts to evaluate the safety, tolerability, and PK of VRG50635 following single and multiple doses in healthy participants. The study will consist of a screening period, onsite dosing phase(s), and follow-up period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VRG50635 | Specified dose on specified days |
| DRUG | Placebo | Specified dose on specified days |
Timeline
- Start date
- 2024-02-29
- Primary completion
- 2024-03-25
- Completion
- 2024-04-08
- First posted
- 2024-02-29
- Last updated
- 2025-12-15
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06286475. Inclusion in this directory is not an endorsement.